Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Inventory (2022 - 2025)

Historic Change in Inventory for Whitehawk Therapeutics (WHWK) over the last 4 years, with Q1 2025 value amounting to -$170000.0.

  • Whitehawk Therapeutics' Change in Inventory rose 6530.61% to -$170000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was -$328000.0, marking a year-over-year decrease of 12588.79%. This contributed to the annual value of -$1.1 million for FY2024, which is 13418.07% down from last year.
  • Whitehawk Therapeutics' Change in Inventory amounted to -$170000.0 in Q1 2025, which was up 6530.61% from -$158000.0 recorded in Q4 2024.
  • Whitehawk Therapeutics' Change in Inventory's 5-year high stood at $2.2 million during Q4 2023, with a 5-year trough of -$630000.0 in Q3 2024.
  • In the last 4 years, Whitehawk Therapeutics' Change in Inventory had a median value of $7000.0 in 2022 and averaged $295384.6.
  • The largest annual percentage gain for Whitehawk Therapeutics' Change in Inventory in the last 5 years was 86138.61% (2023), contrasted with its biggest fall of 470000.0% (2023).
  • Quarter analysis of 4 years shows Whitehawk Therapeutics' Change in Inventory stood at $1.1 million in 2022, then soared by 97.43% to $2.2 million in 2023, then crashed by 107.1% to -$158000.0 in 2024, then fell by 7.59% to -$170000.0 in 2025.
  • Its Change in Inventory stands at -$170000.0 for Q1 2025, versus -$158000.0 for Q4 2024 and -$630000.0 for Q3 2024.